Resveratrol ameliorates diabetes-induced renal damage through regulating the expression of TGF-β1, Collagen IV and Th17/Treg-related cytokines in rats

West Indian Medical Journal

Volumn 63, Issue 1, 2014, Pages 20-25

  Wenbin, Zhou ^a   Guojun, Gao ^a  

^a WEIFANG MEDICAL UNIVERSITY   (China)

Author keywords

Diabetic nephropathy; Renal damage; Resveratrol; Th17 Treg related cytokines

Indexed keywords

COLLAGEN TYPE 4; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 25; INTERLEUKIN 35; RESVERATROL; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; KIDNEY FUNCTION; KIDNEY HOMOGENATE; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; REGULATORY T LYMPHOCYTE; RENAL PROTECTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TH17 CELL;

EID: 84927783876     PISSN: 00433144     EISSN: None     Source Type: Journal    
DOI: 10.7727/wimj.2014.008     Document Type: Article

References (25)

1. Bryan GC, Johnson JA, Dawes L, Samuel C. An assessment of the risk factors for type 2 diabetes among women in rural Jamaica. West Indian Med J 2012; 61: 809-13.
2. Bouaziz A, Zidi I, Zidi N, Mnif W, Zinelabidine HT. Nephropathy following type 2 diabetes mellitus in Tunisian population. West Indian Med J 2012; 61: 881-8.
3. Zhang H, Zhao T, Gong Y, Dong X, Zhang W, Sun S et al. Attenuation of diabetic nephropathy by Chaihuang-Yishen granule through anti-inflammatory mechanism in streptozotocin-induced rat model of diabetics. J Ethnopharmacol 2014; 51: 556-64.
4. Jin DC. Current status of dialysis therapy for ESRD patients in Korea. J Korean Med Assoc 2013, 56: 562-8.
5. Ahn JH, Hong HC, Cho MJ, Kim YJ, Choi HY, Eun CR et al. Effect of eplerenone, a selective aldosterone blocker, on the development of diabetic nephropathy in type 2 diabetic rats. Diabetes Metab J 2012; 36: 128-135.
6. Kajdaniuk D, Marek B, Borgiel-Marek H. Transforming growth factor β1 (TGFβ1) in physiology and pathology. Endokrynol Pol 2013; 64: 384-96.
7. Menè P, Pirozzi N. Potassium channels, renal fibrosis, and diabetes. Diabetes 2013; 62: 2648-50.
8. Zamauskaite A, Yaqoob MM, Madrigal JA, Cohen SB. The frequency of Th2 type cells increases with time on peritoneal dialysis in patients with diabetic nephropathy. Eur Cytokine Netw 1999; 10: 219-26.
9. Czyzewska J, Wasilewska K, Kaminska J, Koper O, Kemona H, Jakubowska I. Assess the impact of concentrations of inflammatory markers IL-6, CRP in the presence of albuminuria in patients with type 2 diabetes. Pol Merkur Lekarski 2012; 32: 98-102.
10. Rakitianskaia IA, Riabov SI, Dubrova AG, Azanchevskaia SV, Riabova TS, Gurkov AS. The role of IL-6 in the development of morphological changes in renal tissue in elderly patients with type 2 diabetes complicated by diabetic nephropathy. Adv Gerontol 2012; 25: 632-7.
11. Wu CC, Sytwu HK, Lu KC, Lin YF. Role of T-cells in Type 2 diabetic nephropathy. Exp Diabetes Res 2011; 2011: 514738. doi: 10.1155/ 2011/514738.
12. Eller K, KirschA, WolfAM, Sopper S, TagwerkerA, Stanzl U et al. Potential role of regulatory T cells in reversing obesity-linked insulin resistance and diabetic nephropathy. Diabetes 2011; 60: 2954-62. doi: 10.2337/db11-0358.
13. Xu J, Su HL, Wang JH, Zhang CH. [Role of CD4+CD25+Foxp3+ regulatory T cells in type 2 diabetic nephropathy]. Nan Fang Yi Ke Da Xue Xue Bao 2009, 29: 137-9. In Chinese
14. Kikodze N, Pantsulaia I, Rekhviashvili Kh, Iobadze M, Jakhutashvili N, Pantsulaia N. Cytokines and T regulatory cells in the pathogenesis of type 1 diabetes. Georgian Med News 2013; 222: 29-35.
15. Ryba-StanislawowskaM, SkrzypkowskaM, Mysliwska J, MysliwiecM. The serum IL-6 profile and Treg/Th17 in patients with type 1 diabetes. Mediators Inflamm 2013; 2013: 205284. doi: 10.1155/2013/205284.
16. Ryba-StanislawowskaM, SkrzypkowskaM, MysliwiecM, Mysliwska J. Loss of the balance between CD4 (+) Foxp3 (+) regulatory T cells and CD4 (+) IL17A (+) Th17 cells in patients with type 1 diabetes. Hum Immunol 2013; 74: 701-7.
17. Jiang B, Guo L, Li BY, Zhen JH, Song J, Peng T et al. Resveratrol attenuates early diabetic nephropathy by down-regulating glutathione s-transferases Mu in diabetic rats. J Med Food 2013; 6: 481-6.
18. Ding DF, You N, Wu XM, Xu JR, Hu AP, Ye XL et al. Resveratrol attenuates renal hypertrophy in early-stage diabetes by activating AMPK. Am J Nephrol 2010; 31: 363-74.
19. Tikoo K, Singh K, Kabra D, Sharma V, Gaikwad A. Change in histone H3 phosphorylation, MAP kinase p38, SIR 2 and p53 expression by resveratrol in preventing streptozotocin induced type I diabetic nephropathy. Free Radic Res 2008; 42: 397-404.
20. Chang CC, Chang CY, Wu YT, Huang JP, Yen TH, Hung LM. Resveratrol retards progression of diabetic nephropathy through modulations of oxidative stress, proinflammatory cytokines, and AMP-activated protein kinase. J Biomed Sci 2011; 18: 47. doi: 10.1186/1423-0127-18-47.
21. Vinik AI, Nevoret ML, Casellini C, Parson H. Diabetic neuropathy. Endocrinol Metab Clin North Am 2013; 42: 747-87.
22. Amiri F, Zarnani AH, Zand H, Koohdani F, Jeddi-Tehrani M, Vafa M. Synergistic anti-proliferative effect of resveratrol and etoposide on human hepatocellular and colon cancer cell lines. Eur J Pharmacol 2013; 718: 34-40.
23. Zhang MH, Feng L, Zhu MM, Gu JF, Jiang J, Cheng XD et al. The antiinflammation effect of moutan cortex on advanced glycation end products- induced rat mesangial cells dysfunction and high-glucose-fat diet and streptozotocin-induced diabetic nephropathy rats. J Ethnopharmacol 2014; 151: 591-600.
24. Haseda F, ImagawaA, Murase-Mishiba Y, Terasaki J, Hanafusa T. CD4+ CD45RA- FoxP3high activated regulatory T cells are functionally impaired and related to residual insulin-secreting capacity in patients with type 1 diabetes. Clin Exp Immunol 2013; 173: 207-16.
25. Ash S, Yarkoni S, Askenasy N. Lymphopenia is detrimental to therapeutic approaches to type 1 diabetes using regulatory T cells. Immunol Res 2014; 58: 101-5. doi: 10.1007/s12026-013-8476-x